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The obesity epidemic continues unabated and currently available pharmacological treatments are not
sufﬁciently effective. Combining gut/brain peptide, GLP-1, with estrogen into a conjugate may represent a
novel, safe and potent, strategy to treat diabesity. Here we demonstrate that the central administration of
GLP-1-estrogen conjugate reduced food reward, food intake, and body weight in rats. In order to
determine the brain location of the interaction of GLP-1 with estrogen, we avail of single-photon
emission computed tomography imaging of regional cerebral blood ﬂow and pinpoint a brain site un-
explored for its role in feeding and reward, the supramammillary nucleus (SUM) as a potential target of
the conjugated GLP-1-estrogen. We conﬁrm that conjugated GLP-1 and estrogen directly target the SUM
with site-speciﬁc microinjections. Additional microinjections of GLP-1-estrogen into classic energy
balance controlling nuclei, the lateral hypothalamus (LH) and the nucleus of the solitary tract (NTS)
revealed that the metabolic beneﬁts resulting from GLP-1-estrogen injections are mediated through the
LH and to some extent by the NTS. In contrast, no additional beneﬁt of the conjugate was noted on food
reward when the compound was microinjected into the LH or the NTS, identifying the SUM as the only
neural substrate identiﬁed here to underlie the reward reducing beneﬁts of GLP-1 and estrogen conju-
gate. Collectively we discover a surprising neural substrate underlying food intake and reward effects of
GLP-1 and estrogen and uncover a new brain area capable of regulating energy balance and reward.
© 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The obesity epidemic continues unabated and is associated with
adverse health consequences - diabetes, cardiovascular disease,/Metabolic Physiology, Insti-
Academy at the University of
30, Gothenburg, Sweden.
P. Skibicka).
ier Ltd. This is an open access articdisability, and increased cancer risk. The currently available phar-
macological treatments are less efﬁcient than expected. Therefore,
there is an urgent need for novel therapies that reduce body weight
more potently than currently available pharmaceutics without
producing undesirable side effects. One potential way to achieve a
more potent weight loss may be by combining multiple anti-
obesity drug targets in one molecule. Polypharmaceutical ap-
proaches, for example targeting the incretin system with an
unimolecular glucagon-like peptide 1 (GLP-1)-estrogen co-agonist,le under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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GLP-1, a gut/brain peptide primarily produced in the intestinal
tract in response to ingested nutrients and by the neurons of the
nucleus of the solitary tract (NTS) of the brainstem (Holst, 2007),
gained interest due to its glucoregulatory (Drucker, 2006) and
appetite suppressing effects (Barrera et al., 2011). The highly se-
lective GLP-1 receptor (GLP-1R) agonist, Exendin-4 (Ex4), is
approved as antidiabetic agent in the treatment of type 2 diabetes
(Byetta®) and anti-obesity treatment (Saxenda®). The steroid hor-
mone estradiol, mainly produced by the ovaries, has also been
implicated as a potential anti-obesity agent (Mauvais-Jarvis et al.,
2013). However, the reproductive endocrine toxicity and oncoge-
nicity limit its clinical application.
The conjugation of GLP-1 to estrogen allows for speciﬁc delivery
of estrogen to GLP-1R expressing tissues without producing the
undesirable side effects. In addition, this selective targeting of es-
trogen receptors to GLP-1R expressing cells is much more effective
in reducing obesity and improving dyslipidemia and hyperglycemia
than activation of either GLP-1 or estrogen receptors (ER) alone
(Finan et al., 2012). The site of action of the weight and food intake
reducing impact remains unknown. Here we hypothesize that the
anti-obesity action of the conjugated GLP-1-estrogen is mediated
by its direct action on CNS GLP-1 and estrogen receptors, which are
co-expressed in several brain areas regulating homeostatic feeding
behavior and metabolism (Shughrue et al., 1997; Merchenthaler
et al., 1999). Hedonically driven feeding may be one of the key
components driving overeating (Berthoud, 2002, 2011; Alsio et al.,
2012). Furthermore the potential impact of the GLP-1-estrogen
conjugate on food-reward behavior has not yet been explored.
In the present study we determine whether peripheral or cen-
tral co-activation of GLP-1 and estrogen receptors impacts on food-
reward behavior. Using single-photon emission computed tomog-
raphy (SPECT) imaging of regional cerebral blood ﬂow (Kolodziej
et al., 2014) and site-speciﬁc microinjections we identify the
supramammillary nucleus (SUM), a brain area largely unexplored
for its role in feeding or reward, as a potential target for the syn-
ergistic activity of the conjugate to regulate food reward. The latter
ﬁnding not only reveals a surprising neural substrate underlying
food intake and reward effects of GLP-1 and estrogen but also un-
covers a new brain area capable of regulating energy balance and
reward.
2. Material and methods
2.1. Animals
Adult Sprague-Dawley rats (200e250 g, Charles River, Germany)
were housed in a 12 h light/dark cycle (lights on at 6 am) with
regular chow and water available ad libitum in their home cages. All
experiments were performed in male rats as the initial study by
Finan et al. (2012) already demonstrated that the GLP-1-estrogen
conjugate exerts the metabolic beneﬁts independently of the
gender. All animal procedures with rats were carried out with
ethical permission and in accordance with the University of Goth-
enburg Institutional Animal Care and Use Committee guidelines.
For functional neuroimaging adult eight week old male C57Bl/6
mice (Charles River, Germany) were used and studies were carried
out in accordance with the German animal welfare laws and
approved by the animal ethics committee of Sachsen-Anhalt.
2.2. Brain surgery
Brain cannulation was performed as previously described
(Skibicka et al., 2011). Brieﬂy, rats were implanted with a guide
cannula under ketamine/xylazine anesthesia at the followingcoordinates: lateral ventricular guide cannula (26 gauge, Plastics
One Roanoke, VA, USA; coordinates: ±1.6 mm from midline,
0.9mmposterior to bregma, and 2.5mmventral from the surface of
the skull, with injector aimed 4.5 ventral to skull); ventral
tegmental area (VTA) guide cannula (±0.75 mm from midline,
5.7mmposterior to bregma, and 6.5mmventral from the surface of
the skull, with injector aimed 8.5 ventral to skull; (Skibicka et al.,
2011); SUM guide cannula (on the midline, 4.7 mm posterior to
bregma, and 7.1 mm ventral from the surface of the skull, with
injector aimed 9.1 ventral to skull); lateral hypothalamus (LH) guide
cannula (±1.5 mm from midline, 2.8 mm posterior to bregma, and
6.8 mm ventral from the surface of the skull, with injector aimed
8.8 ventral to skull); NTS guide cannula (±0.75 mm from midline,
on occipital suture, and 6.9 mm ventral from the surface of the
skull, with injector aimed 8.9 ventral to skull, modiﬁed from
Richard et al. (2015); were attached to the skull with dental acrylic
and jeweler's screws. Following a surgical recovery period (7 days)
placement of the lateral ventricle cannula was veriﬁed by angio-
tensin II (2 ml; 10 ng/ml) administration. Rats, which consumed >5
ml/water within 30 min following injection of angiotensin II were
included in the studies. Correct placement of the VTA, LH and SUM
cannula was conﬁrmed post mortem by injection of India ink at the
same microinjection volume as used for the experiment. NTS in-
jection sites were evaluated by injection of 24 mg of 5-thio-d-
glucose in 0.3 ml of artiﬁcial cerebrospinal ﬂuid (aCSF, Tocris, Bristol,
UK), which induce a sympathoadrenal-mediated glycemic response
if the injections correctly reach the NTS (Ritter et al., 1981). Only
rats with correct placement were included in the study.
2.3. Drugs
GLP-1 control compound and GLP-1-estrogen stable conjugate
were provided by R. DiMarchi (Indiana University, Bloomington, IN,
USA). The conjugate is likely to target nuclear ER, both ERa and ERb
may have a contribution since we previously demonstrated that
both ER knockout mice have a blunted effect of the conjugate
(Finan et al., 2012). The conjugate initiates the classic estrogen
responsive element (ERE)-mediated transcriptional events, though
a contribution from plasma membrane receptors cannot be
excluded (especially considering the relatively rapid onset of the
conjugate impact on reward). In the ﬁrst study we conﬁrmed that
estrogen attachment does not inﬂuence the inherent activity of the
peptide as the binding afﬁnity and the biochemical signaling po-
tency of the conjugate is similar to the parent peptides (Finan et al.,
2012). This allows the ligand-activated endocytosis of GLP-1R at
target cells and ﬁnally drives the intracellular transport of the
conjugated estrogen to reach the intracellular receptors (Finan
et al., 2012). We previously reported that for all metabolic param-
eters measured the stable conjugate offered an advantage
compared to the GLP-1 compound alone, or compared to a labile
conjugate, with a 7.5%weight loss inmice given the labile conjugate
and 23% weight loss in mice that received the stable conjugate
(Finan et al., 2012). Food intake followed the same pattern. Since
the labile conjugate did not have any additional beneﬁts over GLP-1
alone it was proposed that the efﬁcacy of the conjugate likely relies
on concentrating the estrogen into energy balance relevant tissues,
since the estrogen is guided by GLP-1 and released intracellularly
only in tissues expressing GLP-1 receptors. Importantly, the con-
jugate was not only designed to maximize the metabolic beneﬁts
above those of the single agonists but also to avoid the side effects
often seen with GLP-1 activation and to bypass the reproductive
endocrine toxicity and oncogenicity of estrogen (Finan et al., 2012).
b-Estradiol was purchased from Sigma (E4389; St Louis, MO, US),
dissolved in saline (vehicle for subcutaneous injections) or aCSF
(vehicle for central injections).
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To test the impact of GLP-1-estrogen on food-motivated
behavior the sucrose-driven progressive ratio (PR) operant condi-
tioning test was used. Food-induced operant conditioning training
and testing were performed in rat conditioning chambers
(30.5  24.1  21.0 cm; Med-Associates, Georgia, VT, USA) con-
taining a metal grid ﬂoor, two retractable levers with light bulbs
above, and a food pellet dispenser that can deliver 45 mg of sucrose
pellets (Test Diet, Richmond, IN, USA). The training included four
stages: ﬁrst three sessions on ﬁxed ratio (FR) starting with FR1
(single press on the active lever ¼ delivery of one sucrose pellet)
followed by FR3 (3 presses/pellet) and ﬁnally FR5 (5 presses/pellet),
where a minimum of 50 presses per session was required to
graduate to the next FR level. The FR5 was followed by the PR
schedule where the cost of a reward was progressively increased
(Skibicka et al., 2011). PR sessions were continued until a stable
baseline (15% for three consecutive sessions) was reached. During
the FR and the ﬁrst three PR sessions all rats were mildly food
restricted resulting in a gradual loss of about 10% of their initial
body weight over a period of one week.
For the drug testing the following conditions were used: (1) For
subcutaneous (sc.) drug application (1 ml per kg body weight):
vehicle, 2 mg GLP-1-estrogen, 1.87 mg GLP-1, and 0.13 mg estrogen
per kg body weight. (2) For intracerebroventricular (ICV) drug
application (1 ml): vehicle, 0.125 mg GLP-1-estrogen, 0.117 mg GLP-1,
and 0.008 mg estrogen. (3) For VTA (0.5 ml), and SUM (0.3 ml) drug
application: vehicle, 0.075 mg GLP-1-estrogen, 0.07 mg GLP-1, and
0.005 mg estrogen. Satiated rats received the injections early in the
light phase 90 min (sc. injections) or 30 min (central injections)
before the 60 min sucrose reinforced PR operant conditioning.
2.5. SPECT-imaging of regional cerebral blood ﬂow (rCBF)
SPECT-imaging of rCBF was performed similarly as described in
detail in Kolodziej et al. (2014). In brief, awake unrestrained C57Bl/
6J mice were intravenously injected via jugular vein catheters with
the blood ﬂow tracer 99m-technetium hexamethylpropyleneamine
oxime (99mTc-HMPAO) after treatment with GLP-1-estrogen, GLP-
1, or PBS as control. After 99mTc-HMPAO-injection animals were
anesthetized and scanned using a small-animal SPECT/CT scanner.
99mTc-HMPAO is a lipophilic compound that, after ﬂow-dependent
wash-in, is rapidly converted to a hydrophilic compound that re-
mains trapped in the brain and shows no redistribution. The
99mTc-brain distribution as determined in anesthetized animals in
the scanner thus reﬂects the spatial pattern of the average blood
ﬂow during the injection period in the awake state. Jugular vein
catheters (ALZET, Cupertino, USA; 44.5 mm PU, OD: 0.84 mm, ID:
0.36 mm, connected to a 50 mm ALZET connection, OD: 1.02 mm
OD, ID: 0.61 mm, total catheter length 9.5 cm) were implanted into
the right external jugular vein. Following a two days recovery
period, mice were intraperitoneally injected either with 400 mg per
kg body weight (1 ml per kg body weight) GLP-1 (n ¼ 8), GLP-1-
estrogen (n ¼ 7), or PBS (n ¼ 7). After substance application the
jugular vein catheter was connected via a saline-ﬁlled Teﬂon tube
(Tefzel-Tube, CS-Chromatographie Service GmbH, D-52379 Lan-
gerwehe, Germany, OD: 1/16 inch ID: 0.5 mm) of 60 length to a
saline ﬁlled syringe. 30 min after substance application a syringe
ﬁlled with the 99mTc-HMPAO-injection solution was connected to
the Teﬂon tube and the tracer injection started. 99mTc-HMPAOwas
freshly prepared from frozen aliquots of kit preparations for use in
humans (Ceretec™, GE-Healthcare, Buchler, Braunschweig, Ger-
many) (Kolodziej et al., 2014). Compared to the previous study(Kolodziej et al., 2014) the HMPAO-concentration in the aliquots
was doubled so that the volumes of the aliquots could be reduced
(125 ml as compared to 250 ml). Injections were made using a sy-
ringe pump (Harvard Instruments, Holliston, MA, USA). The tracer
was injected over 18 ± 2min. In principle, the tracer can be injected
in much shorter time periods (Kolodziej et al., 2014). We here hy-
pothesized that averaging blood ﬂow over longer periods of time
might be a more suitable approach for visualizing longer-lasting
drug effects. The animals were injected with 99mTc-HMPAO-so-
lutions in volumes of 340 ± 83 ml, the differences in volume being
due to variations in 99mTc-contents in the eluate from the 99mTc-
generators. The ﬂow rate of the tracer-infusion pump was adjusted
according to the differing volumes (16 mle25 ml/min) of the tracer-
solutions. After tracer injection, animals were anesthetized with 2%
isoﬂurane and transferred to the SPECT/CT-scanner (four-head
NanoSPECT/CT™ Mediso/Hungary). The amounts of 99mTc
remaining in the syringe, and teﬂon tube were determined using a
radionuclide calibrator (Aktivimeter Isomed, 2010; Nuklear-
Medizin-Technik Dresden GmbH, Germany) and subtracted from
the initial activity of the tracer solution to calculate the injected
dose. The animals were injected on average with 60 ± 8 MBq of
99mTc.
For SPECT/CT imaging mice were scanned under gas anesthesia
(1.0e1.5% isoﬂurane in 2:1 O2:N2O volume ratio). CT and SPECT
images were co-registered. CT scans were made at 45 kVp, 177 mA,
with 180 projections, 500 msec per projections, 96 mm isotropic
spatial resolution, and reconstructed with the manufacturer's
software (InVivoScope 1.43) at isotropic voxel-sizes of 100 mm.
SPECT scans were made using ten-pinhole mouse brain apertures
with 1.0 mm pinhole diameters providing an isotropic spatial res-
olution of about 0.7 mm FWHM (Kolodziej et al., 2014). 24 pro-
jectionswere acquired during a total scan time of 2 h. Axial FOVwas
20.9 mm. Energy windows were set to the default values of the
NanoSPECT/CT (140 keV ± 5%). SPECT images were reconstructed
using the iterative algorithm of the manufacturer's software (HiS-
PECT™, SCIVIS, Goettingen) at isotropic voxel output sizes of
338 mm.
For data analysis brain 99mTc-distributions were compared in
mice injected with PBS; GLP-1, or GLP-1-estrogen. SPECT/CT images
were manually aligned to a high-resolution MR mouse brain data
set (Ma et al., 2005) based on skull-landmarks of the CTs using the
MPI-Tool™ software (version 6.36, ATV, Advanced Tomo Vision, D-
50169 Kerpen, Germany). SPECT brain data were cut out of the
SPECT-data in the Osirix™ DICOM-viewer (64-bit version 5.7.1)
using a whole-brain volume-of-interest (VOI) made from the
template provided by Ma and colleagues (Ma et al., 2005). Brain
SPECT data were global mean normalized using the MPI-Tool™
software. In the voxelwise analysis unpaired t-tests were made to
compare brain tracer distributions in PBS versus GLP-1 and GLP-1-
estrogen using the MagnAn-software (version 2.4, BioCom GbR, D-
90180 Uttenreuth, Germany). Following common procedures in
small-animal radionuclide imaging (Endepols et al., 2010;
Wyckhuys et al., 2010; Thanos et al., 2013) uncorrected p-values
were used. As a major result at the level of p < 0.01 we found when
testing GLP-1-estrogen against PBS a deactivation in a mid-
rostrocaudal part of the cingulate cortex and a prominent activa-
tion centered on the SUM. Illustrations of the results were made in
Osirix™. Images in Osirix™ were exported as TIFF ﬁles and ar-
ranged using the Photoshop™ software (version CS4).
In order to calculate the differences in mean tracer uptake in the
volume covered by the p < 0.01 voxels in the SUM-region in the
probability maps, signiﬁcant voxels from GLP-1-estrogen versus
PBS injection extending from Bregma 2.1 to 2.8 according to
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VOI using the Plugin function “Growing region” in Osirix™.
Compared to the PBS-group mean tracer uptake in this VOI
increased by 12% in the GLP-1-estrogen group and by 6% in the GLP-
1 group.
2.6. Chow intake and body weight
Immediately after operant testing rats were moved to their
home cages and 1 h and 24 h chow intake was measured. Body
weight was determined immediately before the injection and 24 h
postinjection.
2.7. Pica response
To investigate whether GLP-1 injection induces malaise, the
intake of kaolin (Research Diets, Lane New Brunswick, NJ, USA)
(Mitchell et al., 1976), a non-nutritive substance, was measured in
parallel to chow intake measurements. All rats were exposed to
kaolin before the experimental injections.
2.8. Locomotor activity
For activity measurements rats were injected centrally (ICV)
with vehicle, GLP-1-estrogen, GLP-1 or estrogen, placed into the
activity chamber 30 min later and spontaneous horizontal activity
was recorded for 60 min. Rats had no access to food during the test.
2.9. Statistical analysis
For statistical analysis all parameters were initially tested with
Levene's statistics for homogeneity of variances. At equal variances
data were analyzed by repeated measures analysis of variance
(ANOVA) followed by post hoc Bonferroni or LSD test. If the vari-
ances were not homogeneous parameters were analyzed using the
Generalized Linear Model. All statistical analyses were conducted
using the SPSS software. A p-value <0.05 was considered signiﬁcant
and values are expressed as means ± SEM, unless otherwise stated.
3. Results and discussion
3.1. Subcutaneous co-activation of GLP-1 and estrogen receptors
reduces body weight and food reward
Given the initial data of Finan et al. (2012) demonstrating the
anorexigenic properties of the GLP-1-estrogen conjugate in mice
we ﬁrst tested whether peripheral injection of GLP-1-estrogen in
rats can similarly reduce food intake and body weight. In rats, a
single peripheral, s.c., injection of GLP-1-estrogen (2 mg/kg) signif-
icantly decreased body weight and 24 h food intake (Fig. 1A,B),
whereas 1 h chow intake was unaltered in all groups (data not
shown). The equimolar doses of GLP-1 or estrogen alone were
subthreshold for the anorexic effect, indicating a synergistic effect
of GLP-1-estrogen combination. The reduced feeding response in
GLP-1-estrogen treated animals was not accompanied by the in-
duction of a malaise response, as the ingestion of kaolin (a pica
response) was similar in all compared groups 24 h postinjection
(Fig. 1B). We have previously shown that in mice the weight loss
after the conjugate administration is primarily due to fat loss (Finan
et al., 2012). While water intake was not measured in the current
study, recent literature suggests it is possible that GLP-1 alone re-
duces water intake (McKay et al., 2011; McKay and Daniels, 2013) in
addition to reducing food intake, it is less likely, however, that the
conjugate further reduced water intake since to date the water
intake reducing effects of estrogen were primarily seen in females(Santollo and Daniels, 2015), and the current study is performed in
males. Furthermore the conjugate is equally effective at reducing
body weight in males and females (Finan et al., 2012).
GLP-1 effects on body weight regulation and feeding are largely
mediated by the CNS. Recent literature demonstrates that periph-
eral or central application of GLP-1 or GLP-1 analogs into the VTA,
NAc, NTS, or parabrachial nucleus alters food-reward behavior
(Dickson et al., 2012; Alhadeff et al., 2014; Richard et al., 2015). NTS
GLP-1-producing neurons project directly to the mesolimbic VTA
and NAc (Rinaman, 2010; Dossat et al., 2011; Alhadeff et al., 2012;
Dickson et al., 2012). So far the impact of estrogen on food-
motivated behavior is largely unknown. To determine whether
the GLP-1-estrogen conjugate can change the motivational value of
palatable food, a correlate of food-reward behavior (Hodos, 1961),
we examined the number of sucrose rewards earned under a pro-
gressive ratio (PR) reinforcement schedule after peripheral, s.c.,
administration of the GLP-1, estrogen or the conjugate of the two.
Conjugate-injected rats reduced food-motivated behavior to a
greater extent than rats treated with vehicle, estrogen, or GLP-1
alone as the number of active-lever presses (Fig. 1C) and sucrose
pellets earned (Fig. 1D) were signiﬁcantly decreased. Taken
together these data demonstrate a new role for conjugating GLP-1
with estrogen in the regulation of food reward. The potentiated
reward-suppression of these two substances applied together is in
line with recent ﬁndings demonstrating that estrogen is a critical
regulator of the impact of a GLP-1 analogue, exendin-4, on food
reward in both males and females (Richard et al., 2016).3.2. Central co-activation of GLP-1 and estrogen receptor is
sufﬁcient to decrease food intake and food reward
Central activation of GLP-1R reduces food intake, whereas cen-
tral GLP-1R blockade induces hyperphagia (Tang-Christensen et al.,
1996; Turton et al., 1996; Schick et al., 2003). Several studies
documented that estradiol (E2) suppresses food intake via central
ERa and ERb (Heine et al., 2000; Geary et al., 2001; Asarian and
Geary, 2002; Liang et al., 2002; Gao et al., 2007). Here we
demonstrate that central, ICV, application of GLP-1-estrogen was
sufﬁcient to reproduce the effect of peripheral injection on body
weight and chow intake (Fig. 2A,C), whereas 1 h food intake was
unaffected (Fig. 2B). Conjugate injection was more effective at
reducing body weight and food intake than estrogen alone and
tended to be more potent in comparison to GLP-1, though this
difference did not reach signiﬁcance. The signiﬁcantly reduced 24 h
chow intake after central injection of GLP-1-estrogen or GLP-1 was
not accompanied by a malaise response (Fig. 2C). We then exam-
ined whether central co-activation of GLP-1 and estrogen receptors
affects food-motivated behavior. Acute central GLP-1-estrogen
treatment signiﬁcantly reduced operant PR response for sucrose,
whereas the equimolar doses of GLP-1 or estrogen failed to reduce
food reward when applied individually (Fig. 2D,E). Moreover, in a
separate experiment, GLP-1 or GLP-1-estrogen did not affect gen-
eral locomotor activity at doses that signiﬁcantly reduced chow
intake and food-motivated behavior (Fig. 2F). These data support a
role of the CNS in mediating GLP-1-estrogen effects on food intake
and reward. We additionally show for the ﬁrst time that the
beneﬁcial metabolic effects of GLP-1 and estrogen stimulation are
not necessarily accompanied by general locomotor impairment or
malaise, side-effects often seen with GLP-1 activation in rodents or
humans, at the doses used in the study (Turton et al., 1996; Seeley
et al., 2000; Kinzig et al., 2002; Madsbad et al., 2011; Dickson et al.,
2012). It is of course possible that the results obtained would differ
if higher doses of the conjugate or GLP-1 were used than those
applied in the current study.
Fig. 1. Combining GLP-1 and estrogen in a subcutaneous injection was effective at reducing body weight and food reward. Conjugation of GLP-1 to estrogen led to a synergistic
effect on weight loss (A) and anorexia (B), without inducing malaise as measured by the PICA response (B). The changes in weight and chow intake were associated with a striking
suppression of sucrose-driven food reward behavior as indicated by reduced active lever presses (C) and rewards earned (D). Data represent mean ± SEM. *p<0.05, **p<0.01,
***p<0.001 by comparing vehicle to compound injections unless otherwise stated. Differences between groups were calculated with repeated measures ANOVA followed by post
hoc Bonferroni test (food intake 24h: F(3,45)¼5.6, p<0.005; sucrose pellets: F(3,45)¼24.4, p<0.0001) or generalized linear model (body weight change: Х2(3)¼10.4, p<0.05; active lever
presses: Х2(3)¼45.1, p<0.0001). n¼16.
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GLP-1-estrogen actions on body weight, food intake, and food-
motivated behavior
To ﬁnd the CNS-sites underlying GLP-1-estrogen driven food
reward changes we used a recently developed protocol for SPECT-
imaging of regional cerebral blood ﬂow (Kolodziej et al., 2014) as a
screening tool. The voxelwise analysis revealed signiﬁcant differ-
ences in rCBF after intraperitoneal injection of GLP-1-estrogen, and
GLP-1 in contrast to vehicle-treated animals at p < 0.001 (Fig. 3 and
Supplementary Fig. 1). The 99mTc brain uptake was signiﬁcantly
increased after GLP-1-estrogen injection in an area extending from
the SUM to the posterior hypothalamus and substantia nigra and
was signiﬁcantly reduced in the cingulate area as compared to
vehicle injections (Fig. 3A and Supplementary Fig. 1A). Few signif-
icant voxels were also detected in the left primary somatosensory
cortex and left dorsal thalamus indicating reduced rCBF after GLP-
1-estrogen injection in these regions (Supplementary Fig. 1B). After
injection of GLP-1 the 99mTc brain uptake was found to be signif-
icantly reduced in the left ectorhinal/entorhinal area and in few
voxels within the primary somatosensory cortex (Supplementary
Fig. 1C,D). Isolated voxels indicating increased rCBF after injection
of GLP-1 were found in the right amygdala, cingulum/anterior
cingulate area and left superior colliculus (SupplementaryFig. 1C,D). If the signiﬁcance level is increased to p < 0.01, a sig-
niﬁcant increase in rCBF was also found in the SUM and posterior
hypothalamus after GLP-1 injection alone (Fig. 3B). VOI analysis,
representing the mean differences within the SUM/posterior hy-
pothalamus after injection of GLP-1-estrogen, GLP-1, or vehicle
obtained from added global mean normalized data of single ani-
mals, revealed an increase in 99mTc uptake in this region from
vehicle injection (1.10 m) to GLP-1 injection (1.17 m) and to GE in-
jection (1.25 m) of about 6% in each case (Fig. 3C,D). Thus, SPECT-
imaging revealed the SUM as the main GLP-1-estrogen target
area. The SUM is rather unexplored in the ﬁelds of energy balance
regulation or reward. Nevertheless, a few studies have suggested
that the SUM may participate in reward and feeding control. The
medial part of SUM contains dopamine neurons and receives dense
projections from the LH, including LH orexin neurons (Peyron et al.,
1998; Swanson, 1982). Administration of GABAA receptor antago-
nists into the SUM potently induces intracranial drug self-
administration. This nucleus also mediates reward triggered by
administration of nicotine or the glutamate receptor agonist AMPA
(Ikemoto et al., 2004, 2006). ERb, GPR30, and GLP-1R have been
detected in the SUM (Shughrue et al., 1997; Merchenthaler et al.,
1999; Hazell et al., 2009) suggesting a potential for a direct effect
of the GLP-1-estrogen in this area. GLP-1-estrogen injections into
the SUM performed next further supported this idea as the sucrose-
Fig. 2. Central injection of GLP-1-estrogen was sufﬁcient to reduce body weight and food reward. Body weight was signiﬁcantly reduced after central (intra lateral ventricle)
injection of GLP-1 or GLP-1-estrogen conjugate (A). The impact of the treatment on food intake emerged at 24h after injection (B-C). No changes in malaise were noted (C). The
sucrose-driven food reward behavior was suppressed by the GLP-1-estrogen conjugate as measured by reduced number of active lever presses (D) and sucrose pellets (E).
Importantly the reduced reward behavior was not associated with non-speciﬁc reduction in general motor activity (F). Data represent mean ± SEM. *p<0.05, **p<0.01, ***p<0.001 by
comparing vehicle to compound injections unless otherwise stated. Differences between groups were calculated with generalized linear model (body weight change: Х2(3)¼15.4,
p<0.005; food intake 24h: Х2(3)¼25.5, p<0.00005; active lever presses: Х2(3)¼19.4, p<0.0005; sucrose pellets: Х2(3)¼26.8, p<0.0001). n¼11e12.
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istrationwere reduced to amuch greater extent than by estrogen or
GLP-1 alone (Fig. 4AeD). It is impossible to entirely exclude the
possibility that some injection ﬂuid also reached the VTA, the
neighboring structure that co-express GLP-1 and estrogen re-
ceptors (Shughrue et al., 1997; Merchenthaler et al., 1999). How-
ever, current results demonstrate that the conjugate is ineffective at
the level of the VTA (Fig. 4F,G). The administration of GLP-1 alone
into the VTA resulted in a signiﬁcant suppression of food reward,
which is consistent with previous ﬁndings (Dickson et al., 2012).
Thus we show that, surprisingly, traditional reward-controlling
areas do not contribute to the reward-suppressing effect of the
conjugated GLP-1 with estrogen but instead discover a novel
candidate area, the SUM, to underlie the reward-reducing impact of
GLP-1-estrogen. Since both, GLP-1 and estrogen receptors, are
present in the SUM and direct intra-SUMmicroinjections of GLP-1-
estrogen potently suppressed food reward it is reasonable to
conclude that the molecule hybrid targets the reward system
through a direct action in the SUM. Accordingly we demonstrate
that brain circuitry beyond the classical mesolimbic dopaminergic
system drives food-motivated behavior and place the SUM on the
food reward regulation map certainly warranting future studies on
the role of this nucleus in the regulation of food reward.3.4. GLP-1-estrogen enhances the metabolic beneﬁts when injected
into the LH and the NTS
Since both, GLP-1R and ER, are also co-expressed in more clas-
sical energy balance regulating areas (Shughrue et al., 1997;
Merchenthaler et al., 1999) we determined whether these sites
comprise the CNS target sites of GLP-1-estrogen actions on energyhomeostasis. The compounds were microinjected into the LH and
the NTS; brain areas associated with feeding behavior control
(Schwartz, 2006; Simpson et al., 2009). The LH was a highly sen-
sitive target site for the body weight reduction of the conjugate
(Fig. 5A). Although the NTS GLP-1-estrogen injections failed to
reach signiﬁcance there was an obvious trend (p ¼ 0.16) to body
weight reduction. In addition targeting of the LH and NTS with the
GLP-1-estrogen compound induced a robust reduction in 24 h
feeding response (Fig. 5B). Moreover, in both cases conjugate in-
jection was more efﬁcacious at lowering body weight and food
intake than either GLP-1 or estrogen alone. Thus, by site-speciﬁc
injections we demonstrate that the LH and to some extent the
NTS are involved in GLP-1-estrogen synergy on food intake and
body weight regulation. These results are in line with previous
literature suggesting these two brain nuclei are key neural sub-
strates for energy balance effects of GLP-1. Direct administration of
GLP-1 into the LH signiﬁcantly reduces food intake, whereas in-
jection of Ex9 increases food intake (McMahon andWellman, 1998;
Schick et al., 2003) indicating a physiological role of GLP-1R in this
area in feeding behavior control.
In addition, neuronal processing restricted to the NTS was also
sufﬁcient to mediate the intake-suppressive effects of the conju-
gate. The NTS is the ﬁrst central area processing the gastrointestinal
signals to the brain. Vagal-afferent signals synapse in speciﬁc
subnuclei within the NTS to regulate food intake (Schwartz, 2000).
Direct NTS injections of Ex9 or knockdown of preproglucagon, the
precursor of GLP-1, in the NTS causes hyperphagia and weight gain
(Hayes et al., 2009; Barrera et al., 2011). Activation of GLP-1R in the
NTS, by direct injection of GLP-1 or Ex4, reduces both food intake
and engages NTS noradrenergic neurons (Richard et al., 2015). Also
estrogen can act via ERa on NTS neurons to inhibit feeding (Asarian
Fig. 3. SPECT-imaging revealed the supramammillary nucleus (SUM), a nucleus largely unexplored in the ﬁeld of feeding and reward, as the main GLP-1- estrogen target area.
Differences in mean tracer uptake in the SUM region (arrow) after injection of GLP-1-estrogen (row A) and GLP-1 (row B) versus vehicle (PBS) and corresponding probability maps
(A, B, right column) clearly indicate that blood ﬂow in the SUM was increased speciﬁcally after the administration of GLP-1 conjugated to estrogen. Differences in mean tracer
uptake were calculated from normalized group data. Increases in mean tracer uptake were displayed in red, decreases in blue. Mean tracer uptake within the SUM/posterior
hypothalamus in GLP-1-estrogen, GLP-1, or PBS injected mice (C, D). Hemisections of added global mean normalized data are shown in C. The ROI is highlighted in red including the
SUM and posterior hypothalamus and provides a signiﬁcant increase in tracer uptake after injection of GLP-1-estrogen (**p<0.001) and GLP-1 (*p<0.01) in comparison to PBS
injection (D). G: GLP-1; GE: GLP-1-estrogen.
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cating a potent food-intake reduction after intra-NTS conjugate
infusion are in line with these previous studies showing a role for
both GLP-1 and estrogen in NTS in food intake regulation. That both
hindbrain and hypothalamic nuclei have a key contribution to the
anorexic properties of GLP-1-estrogen is perhaps not surprising
considering that the neural control of energy balance is distributed
across the neuraxis and many food intake regulating signals exert a
similar effect from several CNS sites (Grill, 2006; Skibicka and Grill,
2009; Kanoski et al., 2016). We also note that the SUM, LH, and NTS
may not be the only neural substrates targeted by the conjugate,
and further studies examining more metabolic parameters (for
example blood glucose changes) and different time points may
reveal additional neural targets. One such possible target is the
arcuate nucleus, suggested to be an important mediator of food
intake effects of GLP-1R activation by some studies (Beiroa et al.,
2014; Secher et al., 2014), or an important mediator of blood
glucose changes induced by GLP-1 by other studies (Sandoval et al.,
2008).
Recent literature demonstrates that peripheral or central
application of GLP-1 or GLP-1 analogs into the VTA, NAc, NTS, or
parabrachial nucleus alters food-reward behavior (Dickson et al.,
2012; Alhadeff et al., 2014; Richard et al., 2015). NTS GLP-1-producing neurons project directly to the mesolimbic VTA
(Rinaman, 2010; Dossat et al., 2011; Alhadeff et al., 2012; Dickson
et al., 2012). So far the impact of estrogen on food-motivated
behavior is largely unknown. Nevertheless, a wide range of be-
haviors and neurobiological mechanisms are modulated by estro-
gen, including alterations in a conditioned place preference test and
the neuroprotection of dopamine cells (Küppers et al., 2000; Walf
et al., 2007). In the current study microinjections of GLP-1-
estrogen into the traditional reward-associated area, the VTA,
failed to show a synergistic effect of the conjugate in food-
motivated behavior changes. Thus we speculated that, in addition
to SUM, the LH may be another good candidate neural substrate for
the GLP-1-estrogen impact on food reward since the LH also reg-
ulates reward behavior and serves as an interface between the
hypothalamus and the mesolimbic system (Geisler and Zahm,
2005; Teitelbaum and Epstein, 1962; Thompson and Swanson,
2010). While microinjections into the LH revealed a signiﬁcantly
suppressed food reward by GLP-1-estrogen, GLP-1 alone reduced
reward to the same level (Fig. 5C) indicating that estrogen and GLP-
1 do not synergise to reduce food reward in the LH. Similar results
were obtained with the intra-NTS microinjections, indiating that
consistent with previous studies (Alhadeff and Grill, 2014; Richard
et al., 2015) NTS is an important brain nucleus for GLP-1-induced
Fig. 4. The SUM is a direct target site for the impact of the GLP-1-estrogen conjugate on food-motivated behavior. Intra-SUMmicroinfusion of GLP-1 conjugated to estrogen, but not
free GLP-1 or estrogen, reduced body weight (A) and food intake (B) but did not induce malaise measured by kaolin intake (B). Food reward was also potently reduced by intra-SUM
microinfusion of both GLP-1 alone and GLP-1 conjugated to estrogen (C-D). Notably the conjugate resulted in a synergistic effect on both parameters of food-reward behavior (active
lever presses (C) and number of sucrose rewards earned (D)). Representative tissue section demonstrating SUM injection site (left side) and corresponding rat brain atlas section
(right side) (E). In contrast, the same dose of GLP-1-estrogen conjugate injected into the VTA, the well-established target of GLP-1R action of food reward, did not affect food-
motivated behavior whereas injection of GLP-1 alone reduces the number of sucrose rewards. Active lever presses (F) and number sucrose rewards (G) earned in an operant
lever-pressing paradigm after compound injection into the VTA (n ¼ 21). VTA injection site and corresponding rat brain atlas section (H). Data represent mean ± SEM. *p<0.05,
**p<0.01, ***p<0.001 by comparing vehicle to compound injections unless otherwise indicated. Differences between groups were calculated with repeated measures ANOVA
followed by post hoc Bonferroni (SUM, food intake 24h: F(3,33)¼10.0, p<0.0001; VTA, active lever presses: F(3,60)¼6.2, p<0.001 ; VTA, sucrose pellets: F(3,60)¼5.6, p<0.01) or LSD test
(SUM, body weight change: F(3,33)¼4.9, p<0.001; SUM, sucrose pellets: F(3,33)¼7.3, p<0.001) or generalized linear model (SUM, active lever presses: Х2(3)¼17.3, p<0.001). SN:
substantia nigra; SUM: supramammillary nucleus; Aq: aquaduct; cp: cerebral peduncle; ml: medial lemniscus; VTA: ventral tegmental area.
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GLP-1 and estrogen to reduce food reward. These results highlight
the differential responsivity of different neural substrates to the
conjugate, and show that only select sites mediate the synergistic
effects of the conjugate. Thus it is possible that our effect in
ventricle-injected animals gets diluted since it provides access to
many GLP-1 expressing sites, many of which may not participate in
the added beneﬁt of combining GLP-1 with estrogen, in contrast to
the injection performed at other sites (eg SUM).
In summary, microinjections into key energy balance control-
ling nuclei revealed that the metabolic beneﬁts resulting from GLP-
1-estrogen injections are mediated through the LH and to some
extent by the NTS. In contrast, no additional beneﬁt of the conju-
gate was noted on food reward when the compound wasmicroinjected into the LH or the NTS, leaving the SUM as the only
neural substrate identiﬁed here to underlie the reward reducing
beneﬁts of GLP-1 and estrogen conjugate.
3.5. Conclusions
In conclusion, the data presented here provide clear evidence
that the CNS is a crucial target for GLP-1-estrogenmediated actions
on energy homeostasis and outline a previously unidentiﬁed role of
this compound on food reward. These new insights into the
mechanisms of the combined GLP-1 and estrogen action highlight
the therapeutic potential of a new class of polypharmaceutical
agents for the treatment of the metabolic syndrome. To localize the
site of GLP-1-estrogen synergy on food reward we used a novel
Fig. 5. GLP-1-estrogen enhances the metabolic beneﬁts when injected into the LH and the NTS. Microinjections of GLP-1-estrogen reduces (A) 24h body weight change and (B) 24h
chow intake after compound injection into the LH and NTS (n¼21). No beneﬁcial effects were noted on food reward when GLP-1-estrogen was microinjected into the LH and NTS as
the number of active lever presses (C) and sucrose pellets (D) earned in an operant leverpressing paradigm was reduced to the same level as GLP-1 alone. LH injection site and
corresponding rat brain atlas section (E). Data represent mean ± SEM. *p<0.05, **p<0.01, ***p<0.001 by comparing vehicle to compound injections unless otherwise stated. Dif-
ferences between groups were calculated with repeated measures (ANOVA) followed by post hoc Bonferroni test (NTS, Food intake 24h: F(3,60)¼4.6, p<0.01; LH, active lever presses:
F(3,60)¼6.4, p<0.001; LH, sucrose pellets: F(3,60)¼13.5, p<0.001; NTS, active lever presses: F(3,60)¼6.5, p<0.001; NTS, sucrose pellets: F(3,60)¼10.0, p<0.0001) and Generalized Linear
Model (LH, Body weight change: Х2(3)¼72.8, p<0.0001; LH, Food intake 24h: Х2(3)¼98.5, p<0.0001). LH: lateral hypothalamus; DMH: dorsomedial hypothalamus; VMH: ventro-
medial hypothalamus; Arc: arcuate nucleus.
H. Vogel et al. / Neuropharmacology 110 (2016) 396e406404approach of functional neuroimaging. An important and unex-
pected ﬁnding of the present study is that coactivation of GLP-1 and
estrogen receptors results in a unique activation of the SUM, a brain
area clearly capable of regulating energy balance and reward that
has not been previously indicated for this role. These ﬁndings may
be clinically relevant, since peripheral injections, the applicationroute used in diabetic and obese patients prescribed GLP-1-based
drugs, activated the SUM.Acknowledgements
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